{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:24:19Z","timestamp":1787509459833,"version":"build-2736575974"},"reference-count":95,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Eisai Europe, Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2025.2609499","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:31:26Z","timestamp":1767609086000},"page":"118-134","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["A value assessment of patient-level outcomes and productivity loss for intravenous and subcutaneous lecanemab for patients with early Alzheimer\u2019s disease"],"prefix":"10.1080","volume":"29","author":[{"given":"Riccardo","family":"Ressa","sequence":"first","affiliation":[{"name":"Parexel International","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Ettinger","sequence":"additional","affiliation":[{"name":"Parexel International","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emtiyaz","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Parexel International","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Graham","sequence":"additional","affiliation":[{"name":"Parexel International","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerigo","family":"Ndirangu","sequence":"additional","affiliation":[{"name":"Eisai Inc","place":["Nutley, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen Zabala","family":"Mancebo","sequence":"additional","affiliation":[{"name":"Eisai Europe Ltd","place":["Hatfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Bodnar","sequence":"additional","affiliation":[{"name":"Eisai Europe Ltd","place":["Hatfield, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_8_3_1","unstructured":"US Food and Drug Administration. FDA converts novel Alzheimer\u2019s disease treatment to traditional approval. 2023 [cited September 18 2024]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval."},{"key":"e_1_3_8_4_1","unstructured":"European Medicines Agency. Approval of the marketing authorisation for Leqembi. 2024 [cited January 13 2025]. https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-approval-marketing-authorisation-leqembi-lecanemab_en.pdf."},{"key":"e_1_3_8_5_1","unstructured":"Mayo Clinic. Alzheimer\u2019s treatments: what\u2019s on the horizon?. 2025 [cited November 15 2025]. https:\/\/www.mayoclinic.org\/diseases-conditions\/alzheimers-disease\/in-depth\/alzheimers-treatments\/art-20047780."},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2"},{"key":"e_1_3_8_8_1","volume-title":"Presented at: Alzheimer\u2019s Association International Conference","author":"Sperling R","unstructured":"Sperling R, Selkoe D, Reyderman L, et al. Does the current evidence base support lecanemab continued dosing for early Alzheimer\u2019s disease?. Presented at: Alzheimer\u2019s Association International Conference; July 28-August 1, 2024; Philadelphia, PA, USA."},{"key":"e_1_3_8_9_1","volume-title":"(lecanemab-irmb) injection, for intravenous use","author":"LEQEMBI","year":"2025","unstructured":"LEQEMBI. (lecanemab-irmb) injection, for intravenous use. [package insert]. Nutley, NJ, USA: Eisai Inc; 2025."},{"key":"e_1_3_8_10_1","unstructured":"Medicines & Healthcare Products Regulatory Agency. LEQEMBI summary of product characteristics. Last updated October 11 2025 https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/25273d488040db1ded59c1517a09b9980776dde8."},{"key":"e_1_3_8_11_1","volume-title":"ABSTRACT 104694. Presented at: Alzheimer\u2019s Association International Conference 2025","author":"Penner N","unstructured":"Penner N, Rawal S, Aluri J, et al. Development of subcutaneous lecanemab: establishing the relationship of subcutaneous and intravenous lecanemab formulations. ABSTRACT 104694. Presented at: Alzheimer\u2019s Association International Conference 2025; July 27-31, 2025; Toronto, ON, Canada."},{"key":"e_1_3_8_12_1","volume-title":"Presented at: Clinical Trials on Alzheimer\u2019s Disease","author":"Irizarry M.","unstructured":"Irizarry M. Preliminary update on lecanemab safety in clarity AD open-label extension, including subcutaneous formulation. Presented at: Clinical Trials on Alzheimer\u2019s Disease; October 24-27, 2023; Boston, MA, USA."},{"key":"e_1_3_8_13_1","unstructured":"Eisai. FDA approves LEQEMBI\u00ae IQLIK\u2122 (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer\u2019s disease. 2025. https:\/\/media-us.eisai.com\/2025-08-29-FDA-Approves-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-for-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease."},{"key":"e_1_3_8_14_1","unstructured":"Eisai. Eisai initiated rolling supplemental biologics license application to the U.S. FDA for LEQEMBI\u00ae IQLIK\u2122 (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer\u2019s disease under fast track status. [cited September 30 2025]. https:\/\/www.eisai.com\/news\/2025\/news202560.html."},{"key":"e_1_3_8_15_1","unstructured":"Eisai. Eisai submits new drug application for subcutaneous formulation of \u201cLEQEMBI\u00ae\u201d for the treatment of early Alzheimer\u2019s disease in Japan. 2025. https:\/\/www.eisai.com\/news\/2025\/news202582.html."},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27227"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S55156"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0171"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14341"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261336"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157957"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00021"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00790-2"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_8_25_1","unstructured":"Popay J Roberts H Sowden A et al. Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC Methods Programme. 2006 [cited November 15 2025]. https:\/\/www.researchgate.net\/publication\/233866356_Guidance_on_the_conduct_of_narrative_synthesis_in_systematic_reviews_A_product_from_the_ESRC_Methods_Programme."},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S22265"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205011310020011"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-191055"},{"key":"e_1_3_8_29_1","unstructured":"National Institute for Health and Care Excellence. Draft guidance consultation \u2013 lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer\u2019s disease. 2024 [cited March 14 2025]. https:\/\/www.nice.org.uk\/guidance\/GID-TA11220\/documents\/draft-guidance."},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.8.1091"},{"key":"e_1_3_8_31_1","unstructured":"Office for National Statistics. National life tables: England and Wales. 2022 [cited January 13 2025]. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesenglandandwalesreferencetables."},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03353-w"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000211170"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.01.010"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00272-1"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.81"},{"key":"e_1_3_8_37_1","unstructured":"The French Social Security System. 2025 [cited January 13 2025]. https:\/\/www.cleiss.fr\/docs\/regimes\/regime_france\/an_3.html."},{"key":"e_1_3_8_38_1","unstructured":"La Vanguardia. In 2025 the legal retirement age in Spain rises to 66 years and 8 months. 2025 [cited January 15 2025]. https:\/\/www.lavanguardia.com\/mediterranean\/20250101\/10250593\/legal-retirement-age-increase-66-years-8-months-2025-pension-spain-economy.html."},{"key":"e_1_3_8_39_1","unstructured":"OECD data explorer. Average annual wages. 2024 [cited April 9 2025]. https:\/\/data-explorer.oecd.org\/vis?tm=average%20annual%20wage&pg=0&snb=26&vw=tb&df[ds]=dsDisseminateFinalDMZ&df[id]=DSD_EARNINGS%40AV_AN_WAGE&df[ag]=OECD.ELS.SAE&df[vs]=1.0&dq=ESP%2BITA%2BDEU%2BFRA%2BGBR\u2026.V.&pd=2023%2C&to[TIME_PERIOD]=false&ly[rw]=COMBINED_UNIT_MEASURE%2CREF_AREA."},{"key":"e_1_3_8_40_1","unstructured":"OECD data explorer. Average annual hours actually worked per worker. 2024 [cited April 9 2025]. https:\/\/data-explorer.oecd.org\/vis?lc=en&pg=0&snb=1&vw=tb&df[ds]=dsDisseminateFinalDMZ&df[id]=DSD_HW%40DF_AVG_ANN_HRS_WKD&df[ag]=OECD.ELS.SAE&df[vs]=&pd=2010%2C&dq=AUS%2BAUT%2BBEL%2BCAN%2BCHL%2BCOL%2BCRI%2BCZE%2BDNK%2BEST%2BFIN%2BFRA%2BDEU%2BGRC%2BHUN%2BISL%2BIRL%2BISR%2BITA%2BJPN%2BKOR%2BLVA%2BLTU%2BLUX%2BMEX%2BNLD%2BNZL%2BNOR%2BPOL%2BPRT%2BSVK%2BSVN%2BESP%2BSWE%2BCHE%2BTUR%2BGBR%2BUSA%2BOECD\u2026\u2026._T\u2026.&to[TIME_PERIOD]=false."},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.573"},{"key":"e_1_3_8_42_1","volume-title":"summary of product characteristics]","author":"LEQEMBI (lecanemab)","year":"2025","unstructured":"LEQEMBI (lecanemab). [summary of product characteristics]. Frankfurt am Main, Germany: Eisai GmbH; April; 2025."},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.02.005"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.123"},{"key":"e_1_3_8_46_1","unstructured":"Eurostat. Employment rate by sex age and country of birth. 2024 [cited April 9 2025]. https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/lfsa_ergacob__custom_15061734\/default\/table?lang=en."},{"issue":"5","key":"e_1_3_8_47_1","first-page":"3708","article-title":"Alzheimer\u2019s disease facts and figures","volume":"20","year":"2024","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u20133821.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_8_48_1","unstructured":"BioArctic. New data from LEQEMBI\u00ae (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD. https:\/\/www.bioarctic.com\/en\/new-data-from-leqembi-lecanemab-irmb-phase-3-clarity-ad-study-and-subcutaneous-formulation-presented-at-ctad\/."},{"key":"e_1_3_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04596-3"},{"key":"e_1_3_8_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-024-02311-5"},{"key":"e_1_3_8_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4465"},{"key":"e_1_3_8_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-017-0276-2"},{"key":"e_1_3_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2015.01.002"},{"key":"e_1_3_8_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241241382"},{"key":"e_1_3_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-014-0313-1"},{"key":"e_1_3_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.03.047"},{"key":"e_1_3_8_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu364"},{"key":"e_1_3_8_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_3_8_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9720-1"},{"key":"e_1_3_8_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2022.2085057"},{"key":"e_1_3_8_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-018-0104-1"},{"key":"e_1_3_8_62_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41014"},{"key":"e_1_3_8_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-05154-9"},{"key":"e_1_3_8_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1382-3"},{"key":"e_1_3_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2024.11.004"},{"key":"e_1_3_8_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae015"},{"key":"e_1_3_8_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.827305"},{"key":"e_1_3_8_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-024-01771-0"},{"key":"e_1_3_8_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex071"},{"key":"e_1_3_8_70_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S44947"},{"key":"e_1_3_8_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07640-3"},{"key":"e_1_3_8_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3587-8"},{"key":"e_1_3_8_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241237560"},{"key":"e_1_3_8_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14037"},{"key":"e_1_3_8_75_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1338546"},{"key":"e_1_3_8_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2249232"},{"key":"e_1_3_8_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02985-9"},{"key":"e_1_3_8_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0126-6"},{"key":"e_1_3_8_79_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S316276"},{"key":"e_1_3_8_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-019-0624-z"},{"key":"e_1_3_8_81_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/lxfy2v"},{"key":"e_1_3_8_82_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S206970"},{"key":"e_1_3_8_83_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528586"},{"key":"e_1_3_8_84_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S303279"},{"key":"e_1_3_8_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-022-00726-7"},{"key":"e_1_3_8_86_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S87271"},{"key":"e_1_3_8_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/NAN.0b013e31824d2271"},{"key":"e_1_3_8_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2016.11.004"},{"key":"e_1_3_8_89_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200107000-00004"},{"key":"e_1_3_8_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204543"},{"key":"e_1_3_8_91_1","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2021.56"},{"key":"e_1_3_8_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-91038-8_4"},{"key":"e_1_3_8_93_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-016-4592-0"},{"key":"e_1_3_8_94_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4723-2"},{"key":"e_1_3_8_95_1","unstructured":"La Moncloa. Official website of the president of the government of Spain and the Council of Ministers. 2025 [cited January 1 2025]. https:\/\/www.lamoncloa.gob.es\/lang\/en\/Paginas\/index.aspx."},{"key":"e_1_3_8_96_1","unstructured":"VidaCaixa. The definitive guide to retirement in Spain: everything you need to know (2025). 2025 [cited October 15 2025]. https:\/\/www.vidacaixa.es\/en\/retirement-in-spain#:\u223c:text=Therefore%2C%20in%20order%20to%20take from%20the%20age%20of%2063."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2609499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:05:34Z","timestamp":1768831534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2609499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2609499"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2609499","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}